Zobrazeno 1 - 10
of 61
pro vyhledávání: '"Benoit Baron"'
Autor:
Marco Pavesi, Moisés Mira Flores, Aurea Duran, Josep Gumà, Alessandra Pranzo, Alexis Serikoff, Bernard Rappe, Angus Robinson, Serena Hilman, Benoit Baron, Louis-Marie Dourthe, D. Mott, Steven Joniau, M. Herdman, Stéphane Mallick, Roberto Bordonaro, Maria De Santis, Ugo De Giorgi, Heather Payne
Publikováno v:
International Journal of Cancer. 150:837-846
In randomized clinical trials, the androgen-receptor inhibitor enzalutamide has demonstrated efficacy and safety in metastatic castration-resistant prostate cancer (mCRPC). This study captured efficacy, safety and patient-reported outcomes (PROs) of
Autor:
Benoit Baron, Hiroyoshi Suzuki, Kazuo Nishimura, Go Kimura, Andrew J. Armstrong, Brad Rosbrook, Taro Iguchi, Arnulf Stenzl, Hiroji Uemura, Lucy F. Chen, Futoshi Kunieda, Satoshi Fukasawa, Jennifer Sugg, Hiroaki Matsumoto, Akira Yokomizo
Publikováno v:
Int J Urol
International Journal of Urology
International Journal of Urology
Objective To evaluate the efficacy and safety of enzalutamide plus androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer. Methods A post-hoc analysis of the Japanese subgroup in the phase III, randomized, mult
Autor:
Jeffrey M. Holzbeierlein, Taro Iguchi, Russell Z. Szmulewitz, Benoit Baron, Andrew J. Armstrong, Neal D. Shore, Daniel P. Petrylak, Boris Alekseev, Jennifer Sugg, Arnulf Stenzl, Brad Rosbrook, Arnauld Villers, Arun Azad, Antonio Alcaraz, Lucy F. Chen
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
Journal of Clinical Oncology
Universidad de Barcelona
Journal of Clinical Oncology
PURPOSE Enzalutamide, a potent androgen-receptor inhibitor, has demonstrated significant benefits in metastatic and nonmetastatic castration-resistant prostate cancer. We evaluated the efficacy and safety of enzalutamide in metastatic hormone-sensiti
Autor:
Russell Z. Szmulewitz, Arun Azad, Gabriel P. Haas, F. Gomez-Veiga, D. Petrylak, Antonio Alcaraz, Taro Iguchi, Jeffrey M. Holzbeierlein, Brad Rosbrook, Andrew J. Armstrong, N.D. Shore, Boris Alekseev, Arnulf Stenzl, Benoit Baron, A. Villers
Publikováno v:
European Urology Open Science, Vol 19, Iss, Pp e865-e866 (2020)
Autor:
U. De Giorgi, M. De Santis, S. Mallick, M. Mira Flores, Aurea Duran, M. Herdman, J. Gumà, H. Payne, Roberto Bordonaro, A. Pranzo, S. Joniau, A. Serikoff, Serena Hilman, Benoit Baron, Marco Pavesi, L-M. Dourthe, D. Mott, Angus Robinson, B. Rappe
Publikováno v:
European Urology Open Science, Vol 19, Iss, Pp e881-e882 (2020)
Autor:
Laurence Klotz, Fong Wang, D. Robert Siemens, Ping Lin, Arnauld Villers, Steve van Os, Benoit Baron, Nahla Hasabou, Simon Chowdhury, Neal D. Shore, Axel Heidenreich
Publikováno v:
Journal of Urology. 199:147-154
Enzalutamide significantly prolonged median progression-free survival vs bicalutamide in chemotherapy naïve men with metastatic castration resistant prostate cancer in the TERRAIN (Enzalutamide versus Bicalutamide in Castrate Men with Metastatic Pro
Autor:
Roberto Bordonaro, Aurea Duran, B. Rappe, L. Dourthe, M. De Santis, S. Joniau, U. De Giorgi, M. Mira Flores, Serena Hilman, J. Gumà, A. Serikoff, H. Payne, Benoit Baron, S. Mallick, Angus Robinson, A. Pranzo
Publikováno v:
European Urology Open Science, Vol 19, Iss, Pp e883-e884 (2020)
Autor:
Russell Z. Szmulewitz, Daniel P. Petrylak, Futoshi Kunieda, Boris Alekseev, Robert Morlock, Taro Iguchi, Benoit Baron, Andrew J. Armstrong, Brad Rosbrook, Arnauld Villers, Jeffrey M. Holzbeierlein, Arnulf Stenzl, Krishnan Ramaswamy, Neal D. Shore, Antonio Alcaraz, Arun Azad
Publikováno v:
Journal of Urology. 201
INTRODUCTION AND OBJECTIVES:Potent androgen receptor inhibitor enzalutamide (ENZA) provides benefit in men with castration-resistant prostate cancer (CRPC). ARCHES, a multinational, double-blind, p...
Autor:
Jeffrey M. Holzbeierlein, Brad Rosbrook, Arnauld Villers, Arun Azad, Russell Z. Szmulewitz, Boris Alekseev, N.D. Shore, Daniel P. Petrylak, Krishnan Ramaswamy, Futoshi Kunieda, Arnulf Stenzl, Antonio Alcaraz, Benoit Baron, Robert Morlock, Andrew J. Armstrong, Taro Iguchi
Publikováno v:
Progrès en Urologie. 29:700
Objectifs L’enzalutamide (ENZA) apporte un benefice aux hommes atteints d’un cancer de la prostate resistant a la castration (CPRC). ARCHES, etude de phase III en double aveugle versus placebo (PBO), evalue l’efficacite d’ENZA associe a une s
Autor:
Antonio Alcaraz, Brad Rosbrook, Arnauld Villers, Gabriel P. Haas, Arun Azad, Daniel P. Petrylak, Jeffrey M. Holzbeierlein, Krishnan Ramaswamy, Taro Iguchi, Russell Z. Szmulewitz, Robert Morlock, Benoit Baron, N.D. Shore, Arnulf Stenzl, Boris Alekseev, Andrew J. Armstrong
Publikováno v:
Annals of Oncology. 30:v332-v333